​

Palvella Therapeutics Ownership | Who Owns Palvella Therapeutics?

OverviewForecastFinancialsChartTranscripts

Palvella Therapeutics Ownership Summary

Palvella Therapeutics is owned by 107.85% institutional investors, 11.59% insiders. Suvretta capital management is the largest institutional shareholder, holding 8.68% of PVLA shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 2.79% of its assets in Palvella Therapeutics shares.

PVLA Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockPalvella Therapeutics107.85%11.59%-19.44%
SectorHealthcare Stocks 50.59%12.40%37.01%
IndustryBiotech Stocks 49.10%12.14%38.76%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Suvretta capital management1.14M8.68%$173.51M
Jennison associates960.62K7.34%$146.80M
Blackrock funding, inc. /de918.36K7.02%$140.34M
Frazier life sciences management882.40K6.74%$134.85M
First light asset management771.90K5.90%$117.96M
Bvf inc/il672.79K5.14%$102.82M
Vanguard group560.62K5.07%$58.68M
State street653.17K4.99%$99.82M
Price t rowe associates inc /md/638.87K4.88%$97.63M
Vanguard capital management513.79K3.93%$78.52M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Clio asset management86.34K10.49%$13.19M
First light asset management771.90K7.17%$117.96M
Suvretta capital management1.14M3.17%$173.51M
Frazier life sciences management882.40K2.94%$134.85M
Bvf inc/il672.79K2.63%$102.82M
First turn management156.45K2.56%$23.91M
Act capital management22.50K2.25%$3.44M
Bioimpact capital204.03K1.90%$31.18M
Avidity partners management lp70.00K1.71%$10.70M
Lisanti capital growth42.98K1.44%$6.57M

Top Buyers

HolderShares% AssetsChange
Jennison associates960.62K0.09%320.01K
Price t rowe associates inc /md/638.87K0.01%236.30K
Blackrock funding, inc. /de918.36K0.00%231.50K
State street653.17K0.00%194.17K
Orbimed advisors292.36K0.83%157.76K

Top Sellers

HolderShares% AssetsChange
Summit partners public asset management---389.42K
Adams street partners---298.99K
Bvf inc/il672.79K2.63%-288.20K
Perceptive advisors---266.29K
Nantahala capital management---250.06K

New Positions

HolderShares% AssetsChangeValue
Bellevue group155.00K0.50%155.00K$23.69M
Hsbc50.00K0.00%50.00K$7.64M
Silvercrest asset management group39.87K0.04%39.87K$6.09M
Sixth street partners management company32.58K0.00%32.58K$4.98M
Mutual of america capital management31.32K0.05%31.32K$4.79M

Sold Out

HolderChange
Ameritas advisory services-1.00
Rockefeller capital management-5.00
Western wealth management-6.00
Twin peaks wealth advisors-7.00
Physician wealth advisors-8.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20262068.42%14,112,1326.85%1071.06%127-3.79%4338.71%
Mar 31, 202618626.53%13,145,25834.69%1161.50%12930.30%30-
Dec 31, 202590-11.76%4,478,390-47.47%400.68%61-8.96%15-21.05%
Sep 30, 202552-16.13%2,330,158-59.04%210.80%33-19.51%1122.22%
Jun 30, 20256562.50%5,909,71115.35%532.47%4491.30%9125.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
State Street® SPDR® S&P® Biotech ETF402.42K2.79%924.00
Vanguard Morn Total Stk Mkt Idx Investor388.39K2.71%26.70K
Vanguard Total Stock Mkt Idx Inv388.39K2.71%26.70K
Vanguard MStar Total Stk Mkt Idx Invest389.68K2.70%1.29K
iShares Russell 2000 ETF277.24K1.92%-4.90K
Federated Hermes Kaufmann Growth276.56K1.92%-
Federated Hermes Kaufmann R276.56K1.92%-
PGIM Jennison Small Company A237.76K1.65%34.86K
Eventide Healthcare & Life Sciences I231.48K1.61%129.74K
MEDICAL BioHealth EUR Acc210.63K1.47%21.39K

Recent Insider Transactions

DateNameRoleActivityValue
Aug 19, 2026Goin Kathleen Chief Operating OfficerSell$61.20K
Aug 19, 2026Goin Kathleen Chief Operating OfficerSell$15.87K
Aug 19, 2026Goin Kathleen Chief Operating OfficerSell$227.09K
Aug 19, 2026Goin Kathleen Chief Operating OfficerSell$303.29K
Aug 19, 2026Goin Kathleen Chief Operating OfficerSell$47.34K

Insider Transactions Trends

DateBuySell
2026 Q3-9
2026 Q2-11
2026 Q137
2025 Q4-3
2025 Q22-

PVLA Ownership FAQ

Who Owns Palvella Therapeutics?

Palvella Therapeutics shareholders are primarily institutional investors at 107.85%, followed by 11.59% insiders and -19.44% retail investors. The average institutional ownership in Palvella Therapeutics's industry, Biotech Stocks , is 49.10%, which Palvella Therapeutics exceeds.

Who owns the most shares of Palvella Therapeutics?

Palvella Therapeutics’s largest shareholders are Suvretta capital management (1.14M shares, 8.68%), Jennison associates (960.62K shares, 7.34%), and Blackrock funding, inc. /de (918.36K shares, 7.02%). Together, they hold 23.04% of Palvella Therapeutics’s total shares outstanding.

Does Blackrock own Palvella Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Palvella Therapeutics.

Who is Palvella Therapeutics’s biggest shareholder by percentage of total assets invested?

Clio asset management is Palvella Therapeutics’s biggest shareholder by percentage of total assets invested, with 10.49% of its assets in 86.34K Palvella Therapeutics shares, valued at 13.19M$.

Who is the top mutual fund holder of Palvella Therapeutics shares?

State Street® SPDR® S&P® Biotech ETF is the top mutual fund holder of Palvella Therapeutics shares, with 2.79% of its total shares outstanding invested in 402.42K Palvella Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools